A- A A+

Optimally Choosing Medication Type for Patients With Opioid Use Disorder

Kara E. Rudolph; Nicholas T. Williams; Iván Díaz; Sean X. Luo; John Rotrosen; Edward V. Nunes

Am J Epidemiol. 2023;192(5):748-756. 


Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. 

Saloner B, Whitley P, Dawson E, Passik S, Gordon AJ, Stein BD. 

Addiction. 2023 May 9. doi: 10.1111/add.16180. Epub ahead of print. PMID: 37158468.


Weight change among patients engaged in medication treatment for opioid use disorder: a scoping review. 

Carr MM, Lou R, Macdonald-Gagnon G, Peltier MR, Funaro MC, Martino S, Masheb RM. 

Am J Drug Alcohol Abuse. 2023 May 18:1-15. doi: 10.1080/00952990.2023.2207720. Epub ahead of print. PMID: 37200510.



Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies

Degenhardt, Louisa et al.

The Lancet Psychiatry, Volume 0, Issue 0 



Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment. 

Pan Y, Feaster DJ, Odom G, Brandt L, Hu MC, Weiss RD, Rotrosen J, Saxon AJ, Luo SX, Balise RR. 

Drug Alcohol Depend Rep. 2022 Dec;5:100128. doi: 10.1016/j.dadr.2022.100128. Epub 2022 Dec 5. PMID: 36644227; PMCID: PMC9838120.


Preliminary attitudes on medications for opioid use disorders (MOUDs) in Southeastern Switzerland and New York City. 

Castillo F, Scalise D, Hernandez D, Gupta R, Basaraba CN, Corbeil T, Comer SD, Schneeberger AR. 

J Addict Dis. 2023 Jan-Mar;41(1):91-97. doi: 10.1080/10550887.2022.2067463. Epub 2022 Apr 22. PMID: 35451354; PMCID: PMC9587133.


Using machine learning to study the effect of medication adherence in Opioid Use Disorder. 

Warren D, Marashi A, Siddiqui A, Eijaz AA, Pradhan P, Lim D, et al. (2022) 

PLoS ONE 17(12): e0278988. doi.org/10.1371/journal.pone.0278988


Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory

Teck, Joseph Tay Wee et al.

The Lancet Psychiatry, Volume 10, Issue 1, 50 - 64 



Suboptimal dosing of opioid agonist treatments - a Literature Review 

Al-Dewaissan F.B.A.A., Hill D., Evans L., and Luz T.C.B.




Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs. 

Ohlendorf E, Perez-Correa A, Riback L, Ghiroli M, Lopez-Castro T, Fox AD. 

J Addict Med. 2022 Oct 18. doi: 10.1097/ADM.0000000000001093. Epub ahead of print. PMID: 36255107.



A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence. 

Greenwald MK, Ghosh S, Winston JR. 

Contemp Clin Trials Commun. 2022 Oct 18;30:101018. doi: 10.1016/j.conctc.2022.101018. PMID: 36303593; PMCID: PMC9593273.


Association between Prescribers' Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability. 

Adzrago D, Paola AD, Zhu J, Betancur A, Wilkerson JM. 

Healthcare (Basel). 2022 Sep 9;10(9):1733. doi: 10.3390/healthcare10091733. PMID: 36141345; PMCID: PMC9498711.


Opioid Dose Trajectories and Associations With Mortality, Opioid Use Disorder, Continued Opioid Therapy, and Health Plan Disenrollment. 

Binswanger IA, Shetterly SM, Xu S, et al. 

JAMA Netw Open. 2022;5(10):e2234671. doi:10.1001/jamanetworkopen.2022.34671


Opioid agonist treatment for people who are dependent on pharmaceutical opioids. 

Nielsen S, Tse WC, Larance B. 

Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD011117. doi: 10.1002/14651858.CD011117.pub3. PMID: 36063082; PMCID: PMC9443668.



Managing Opioid Withdrawal in an Outpatient Setting With Lofexidine or Clonidine. 

Gripshover J, Kosten T. 

Cureus. 2022 Aug 3;14(8):e27639. doi: 10.7759/cureus.27639. PMID: 36072176; PMCID: PMC9437420.


USA. Opioid Addiction Treatment – A Guide for Patients, Families and Friends

ASAM – American Society of Addiction Medicine, 2016


MOUD saves lives, especially after 60 days, and the longer the better. 

Williams, AR. 

Addiction. 2022. doi.org/10.1111/add.16043 


Opium tincture versus methadone for opioid agonist treatment: A randomized controlled trial, 

Nikoo, M., Kianpoor, K., Nikoo, N., Javidanbardan, S., Kazemi, A., Choi, F., Vogel, M., Gholami, A., Tavakoli, S., Wong, J. S. H., Moazen-Zadeh, E., Givaki, R., Jazani, M., Mohammadian, F., Markazi Moghaddam, N., Schütz, C., Jang, K., Akhondzadeh, S., and Krausz, M. (2022) 

Addiction. doi.org/10.1111/add.16030. 



Comparison of Lapse Rate in Drug Dependent Patients in 2 Methods of Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment. 

Vafaeinasab M, Zare H, Dehghani A, Malek S, Dehghani-Tafti M, Sarebanhassanabadi M. 

Subst Abuse. 2022 Jul 22;16:11782218221112502. doi: 10.1177/11782218221112502. PMID: 35903309; PMCID: PMC9315257.


A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder. 

Galaj E, Bi GH, Klein B, Hempel B, Shaik AB, Gogarnoiu ES, Friedman J, Lam J, Rais R, Reed JF, Bloom SH, Swanson TL, Schmachtenberg JL, Eshleman AJ, Janowsky A, Xi ZX, Newman AH. 

Neuropsychopharmacology. 2022 Jul 25:1–10. doi: 10.1038/s41386-022-01379-1. Epub ahead of print. PMID: 35879349; PMCID: PMC9309443.


Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.

Sadek J, Saunders J. 

BMC Psychiatry. 2022 Jul 30;22(1):516. doi: 10.1186/s12888-022-04175-9. PMID: 35908052; PMCID: PMC9338516.


The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance. 

Meyers-Pantele SA, Mittal ML, Jain S, Sun S, Rammohan I, Fairbairn N, Milloy MJ, DeBeck K, Hayashi K, Werb D. 

Subst Abuse Treat Prev Policy. 2022 May 19;17(1):39. doi: 10.1186/s13011-022-00470-6. PMID: 35590419; PMCID: PMC9118611.


The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review. 

Jordan CG, Kennalley AL, Roberts AL, Nemes KM, Dolma T, Piper BJ. 

Pharmacy (Basel). 2022 Apr 19;10(3):48. doi: 10.3390/pharmacy10030048. PMID: 35645327; PMCID: PMC9149874.


What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings. 

Hooker SA, Sherman MD, Lonergan-Cullum M, Nissly T, Levy R. 

J Subst Abuse Treat. 2022 May 20:108804. doi: 10.1016/j.jsat.2022.108804. Epub ahead of print. PMID: 35643586.



What factors influence retention in buprenorphine and methadone treatment?

Medication treatments for opioid use disorder are effective lifesaving therapies, and studies suggest that longer treatment durations result in better patient outcomes (e.g., reduced overdose death risk, less use of ambulatory care services). Identifying the factors that best predict retention can ultimately help us develop and roll out strategies to enhance retention. In this study, the researchers examined which factors were the strongest predictors of medication retention in an Australian sample. (Recovery Research Institute, USA, 22.04.2022)


Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. 

Lim J, Farhat I, Douros A, Panagiotoglou D (2022) 

PLoS ONE 17(3): e0266142. doi.org/10.1371/journal.pone.0266142


Review of medication-assisted treatment for opioid use disorder. 

Ghanem N, Dromgoole D, Hussein A, Jermyn RT. 

J Osteopath Med. 2022 Mar 14. doi: 10.1515/jom-2021-0163. Epub ahead of print. PMID: 35285220.


Update Suchtmedizin: Neue Optionen in der Substitution

Zu Substitution stehen heute zahlreiche Substanzen und Darreichungsformen zur Verfügung. In den letzten Jahren sind insbesondere retardierte Präparate hinzu gekommen, so dass mittlerweile eine auf individuelle Bedürfnisse zugeschnittene Substitution möglich ist. (Richard Kamm, München, Praxis Concept München, in: hiv&more 4/2021


Interim opioid agonist treatment for opioid addiction: a systematic review. 

Samsó Jofra L, Puig T, Solà I, Trujols J. 

Harm Reduct J. 2022 Jan 29;19(1):7. doi: 10.1186/s12954-022-00592-x. PMID: 35090475; PMCID: PMC8800211.


Opioid agonist treatment for self-harm and suicide prevention

Nestadt, Paul S et al.

The Lancet Psychiatry, Volume 9, Issue 2, 100 - 101